Format

Send to

Choose Destination
Hepatol Int. 2018 Nov;12(6):500-509. doi: 10.1007/s12072-018-9896-4. Epub 2018 Sep 20.

A changing paradigm: management and treatment of the HCV/HIV-co-infected patient.

Author information

1
Division of Clinical Care and Research, Institute of Human Virology, University of Maryland, Baltimore, MD, USA.
2
Division of Gastroenterology and Hepatology, Department of Medicine, University of Maryland, Baltimore, MD, USA.
3
Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA. shermake@ucmail.uc.edu.

Abstract

Hepatitis C virus (HCV) treatment in HIV/HCV co-infected individuals has renewed relevance given the ongoing opioid crisis and rise of new HIV and HCV infections associated with injection drug use. Patients co-infected with HIV and HCV demonstrate increased rates of hepatic fibrosis, progression to liver failure, and liver-related mortality. HIV co-infection does not impact outcomes of current HCV treatments, and patients should be treated the same as HCV mono-infected persons, though attention to drug:drug interactions is required. In this review, we discuss the mechanisms mediating injury to the liver in HIV mono-infection and HIV/HCV co-infection, and present the landmark trials of HCV treatment in HIV-infected individuals.

KEYWORDS:

Co-infection; DAA; Drug–drug interactions; HCV; HIV

PMID:
30238230
DOI:
10.1007/s12072-018-9896-4

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center